Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLNN 
Clene Inc. (CLNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CLNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.43
1 Year Target Price $30.43
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.74% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 100.70M USD | Price to earnings Ratio - | 1Y Target Price 30.43 |
Price to earnings Ratio - | 1Y Target Price 30.43 | ||
Volume (30-day avg) 6 | Beta 0.62 | 52 Weeks Range 2.28 - 12.75 | Updated Date 10/31/2025 |
52 Weeks Range 2.28 - 12.75 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -21718.52% |
Management Effectiveness
Return on Assets (TTM) -52.86% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 94221459 | Price to Sales(TTM) 352.1 |
Enterprise Value 94221459 | Price to Sales(TTM) 352.1 | ||
Enterprise Value to Revenue 329.45 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 10069970 | Shares Floating 7174427 |
Shares Outstanding 10069970 | Shares Floating 7174427 | ||
Percent Insiders 30.84 | Percent Institutions 16.43 |
Upturn AI SWOT
Clene Inc.
Company Overview
History and Background
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. It was founded to advance bioenergetics-based therapies, utilizing catalytic nanocrystals.
Core Business Areas
- Neurology: Development of novel therapies for neurodegenerative diseases, focusing on remyelination and neuroprotection. Lead product candidates target multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
Leadership and Structure
Rob Etherington serves as President and CEO. The company has a board of directors and operates with functional departments including R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- CNM-Au8 (Gold Nanocrystals): Investigational drug for neurological diseases (MS, ALS, Parkinson's). Aims to improve neuronal survival and function. Currently in clinical trials. Market share is zero currently as is not approved for use. Competitors for this are drugs currently used to treat symptoms of MS, ALS and Parkinson's (depending on the condition CNM-Au8 is being investigated for). Competitors include Biogen (BIIB), Novartis (NVS) and Teva Pharmaceutical Industries (TEVA).
- CNM-ZnAg (Silver-Zinc Nanocrystals): Investigational drug for wound healing. Current market share is zero as it's not an approved drug. Competitors would be those with wound healing products such as Smith & Nephew (SNN), Integra LifeSciences (IART) and Mlnlycke Health Care.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. There's a growing demand for effective treatments for neurodegenerative diseases due to aging populations.
Positioning
Clene Inc. is a smaller player focused on innovative nanocrystal technology targeting cellular bioenergetics. Its competitive advantage lies in its novel approach to treating neurological disorders.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapeutics is estimated to be in the tens of billions of dollars annually. Clene Inc. aims to capture a portion of this market with its novel therapies pending FDA approval.
Upturn SWOT Analysis
Strengths
- Novel nanocrystal technology platform
- Focus on unmet medical needs in neurodegenerative diseases
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Lack of established commercial infrastructure
- High risk of drug development failure
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased awareness and acceptance of bioenergetics-based therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Generic competition
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- TEVA
- LLY
Competitive Landscape
Clene Inc. competes with established pharmaceutical companies with more resources and established products. Clene's advantage is its novel technology, but it must demonstrate clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Growth is currently driven by clinical trial advancements and securing funding. Historical data reflects its status as a development-stage company.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates vary widely and are highly speculative.
Recent Initiatives: Recent initiatives include advancing CNM-Au8 through clinical trials for MS, ALS, and Parkinson's disease.
Summary
Clene Inc. is a high-risk, high-reward biopharmaceutical company with an innovative technology platform. Its success hinges on positive clinical trial outcomes and regulatory approvals. The company needs to manage its cash reserves carefully while navigating a competitive landscape, with significant competitors having greater resources. Clene's advantage comes from its cutting edge nanocrystal technology. They must secure partnerships to offset risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.